Endothelial senescence, characterized by an irreversible cell cycle arrest, oxidative stress, and downregulation of endothelial nitric oxide synthase (eNOS), has been shown to promote endothelial dysfunction leading to the development of age-related vascular disorders. This study has assessed the possibility that the local angiotensin system promotes endothelial senescence in coronary artery endothelial cells and also the protective effect of the Crataegus extract WS1442, a quantified hawthorn extract. Serial passaging from P1 to P4 (replicative senescence) and treatment of P1 endothelial cells with the eNOS inhibitor L-NAME (premature senescence) promoted acquisition of markers of senescence, enhanced ROS formation, decreased eNOS expression, and upregulation of angiotensin-converting enzyme (ACE) and AT1 receptors. Increased SA-β-gal activity and the upregulation of ACE and AT1R in senescent cells were prevented by antioxidants, an ACE inhibitor, and by an AT1 receptor blocker. WS1442 prevented SA-β-gal activity, the downregulation of eNOS, and oxidative stress in P3 cells. These findings indicate that the impairment of eNOS-derived nitric oxide formation favors a pro-oxidant response triggering the local angiotensin system, which, in turn, promotes endothelial senescence. Such a sequence of events can be effectively inhibited by a standardized polyphenol-rich extract mainly by targeting the oxidative stress.
senescence-associated-β-galactosidase (SA-β-gal) as a histochemical marker, has been observed overlying atherosclerotic plaques of human coronary arteries and thoracic aortas of patients with ischemic heart diseases (7) . High levels of vascular senescence have also been observed in the aortic arch of spontaneously hypertensive rats (8) and in the aorta of diabetic rats (9) . Studies with cultured cells have indicated that endothelial cell senescence is associated with the downregulation of endothelial nitric oxide synthase (eNOS), the induction of a proinflammatory state, and DNA damages (10) . In addition, the overexpression of endothelial p53 induced endothelial dysfunction and decreased nitric oxide (NO) bioavailability in rat aortic sections and the downregulation of eNOS in cultured endothelial cells (11) .
Oxidative stress has been suggested to be a major contributor to the development of aging-related endothelial dysfunction by reducing the bioavailability of both the endothelial NO and the endotheliumdependent hyperpolarization response, and possibly also by inducing endothelium-dependent contractile responses (12) (13) (14) . Indeed, a high level of oxidative stress is observed throughout the aged arterial wall, which has been suggested to involve several sources of reactive oxygen species (ROS) including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondria, uncoupled eNOS, and cyclooxygenases (12, 13, 15) . Moreover, previous studies have shown that the NADPH oxidase inhibitor apocynin improved aging-related blunted endothelium-dependent relaxations in human microvessels, mice aortas, and in the rat mesenteric artery (12, 14, 16, 17) , and the antioxidant vitamin C enhanced the blunted acetylcholine-induced forearm blood flow in old subjects (15) . An improved aging-related endothelial dysfunction and vascular oxidative stress have also been observed in response to several natural antioxidant treatments including chronic intake of grape-derived polyphenols and a polyphenol-rich Crataegus extract (13, 17, 18) . Besides their antioxidant properties, these polyphenol-rich products may also improve the endothelial dysfunction by inducing a sustained PI3-kinase/Akt-dependent activation of eNOS subsequent to the phosphorylation of the activator site Ser1177, and possibly also by increasing the expression of eNOS (19, 20) .
Several lines of evidence suggest that the angiotensin system is a major contributor to the aging-related endothelial dysfunction. Indeed, both angiotensin-converting enzyme (ACE) and AT1 receptors are upregulated within the old arterial wall, and treatments with either an ACE inhibitor or an AT1 receptor antagonist prevented aging-related endothelial dysfunction (21) (22) (23) . Therefore, the aim of the present study was to determine the possibility that the local angiotensin system triggers the redox-sensitive induction of endothelial senescence using a model of replicative senescence and of premature senescence induced by the inhibition of the eNOS-derived NO formation in cultured porcine coronary artery endothelial cells and to determine whether such an effect is prevented by a polyphenol-rich quantified Crataegus extract.
Material and Methods

Crataegus Special Extract WS1442
Crataegus WS1442 is a special dry extract obtained from leaves with flowers of selected hawthorn species (Crataegus oxyacantha/Crataegus monogyna) by extraction with 45% (w/w) aqueous ethanol (drug/extract ratio 4-6.6:1). The extract is adjusted to a content of 17.3%-20.1% oligomeric procyanidins.
Chemicals
Unless stated otherwise, all chemicals and solvents were from Sigma-Aldrich (Sigma-Aldrich Chemie SARL, St Quentin Fallavier, France).
Isolation and Culture of Coronary Artery Endothelial Cells
Pig hearts were collected from the local slaughterhouse (COPVIAL, Holtzheim, France) and endothelial cells were isolated from the left circumflex coronary arteries as described previously (24) . Briefly, left circumflex coronary arteries were excised from fresh heart, cleaned of adhesive conjunctive tissues, and the remaining blood was flushed with cold phosphate-buffered saline (PBS) without calcium. Endothelial cells were isolated by collagenase treatment (type I, Worthington Biochemicals Corp., Lakewood, NJ) at 1 mg/mL for 12 minutes at 37°C. Endothelial cells were cultured in culture dishes containing medium MCDB 131 (Life Technologies SAS, St Aubin, France) and 15% fetal serum supplemented with penicillin (100 U/mL), streptomycin (100 U/mL), fungizone (250 mg/mL), and L-glutamine (2 mM, all from Lonza, Levallois-Perret, France) and grown for 48-72 hours (passage 0). To prepare cultures for passages 1 to 4, endothelial cells were detached with trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; Life Technologies SAS) and further passaged at a ratio of 1:3 at regular intervals until senescence was reached. The medium was changed every 48 hours.
Fluorescence Detection of SA-β-gal Activity
To measure SA-β-gal activity by flow cytometry, we used the fluorogenic substrate C 12 FDG (5-dodecanoylaminofluorescein Di-β-D-galactopyranoside, Invitrogen, Life Technologies SAS). This compound is a membrane permeable, nonfluorescent substrate of β-galactosidase, which after hydrolysis of the galactosyl residues emits green fluorescence and remains confined within the cell. Endothelial cells were pretreated with chloroquine (300 µM) for 1 hour to increase the internal pH of lysosomes. Chloroquine is a weak base that accumulates in lysosomes, raising the pH to approximately 6. C 12 FDG (33 µM) was then added to the pretreatment medium (without phenol red), and the incubation was continued for 1 hour. At the end of the incubation period, cultures were washed with icecold PBS. Cells were resuspended following trypsinization and analyzed immediately using a flow cytometer (FACScan, BD Biosciences, San Jose, CA). Data were acquired and analyzed with Cellquest software (Becton Dickinson). Light scatter parameters were used to eliminate dead cells and subcellular debris. The C 12 -fluorescein signal was measured using the FL1 detector and SA-β-gal activity was estimated using the median fluorescence intensity of the population. Autofluorescence, as assessed in parallel in cells not exposed to C 12 FDG, was negligible.
Determination of Oxidative Stress in Endothelial Cells
The redox-sensitive fluorescent dye dihydroethidium (DHE) was used to evaluate the in situ formation of ROS. Endothelial cells were treated with DHE (5 µM) for 30 minutes at 37°C in a lightprotected manner to determine the in situ formation of ROS. To determine the source of ROS, endothelial cells were incubated with several inhibitors including L-NAME (NO synthase inhibitor, 1 mM), N-acetyl cysteine (NAC, a non specific antioxidant, 1 mM), apocynin (a NADPH oxidase inhibitor, 300 µM), or indomethacin (a cyclooxygenase inhibitor, 30 µM) for 30 minutes at 37°C before the addition of DHE. Endothelial cells were then washed and analyzed for ethidium fluorescence using a flow cytometer (FACScan, BD Biosciences). Data were acquired and analyzed with Cellquest software.
Western Blotting
After treatment, cells were washed twice with PBS and then lysed in extraction buffer (composition in mM: Tris/HCl 20 [pH 7.5], NaCl 150, Na 3 VO 4 1, sodium pyrophosphate 10, NaF 20, okadaic acid 0.01, a tablet of protease inhibitor [Complete, Roche], and 1% Triton X-100 [Euromedex, Souffelweyershem, France]). Total proteins (10 or 30 µg) were separated on 8% or 12% sodium dodecyl sulfatepolyacrylamide gels at 100 V for 2 hours and transferred electrophoretically in polyvinylidene difluoride membranes (GE healthcare, Vélizy-Villacoublay, France) at 100 V for 2 hours. Membranes were incubated with blocking buffer (Tris-buffered saline solution and 0.1% Tween 20 [Euromedex]) containing 3% bovine serum albumin for 1 hour. For detection of proteins, membranes were incubated with the respective primary antibody: rabbit polyclonal anti-eNOS (diluted 1:1.000; BD Biosciences, Le Pont de Claix, France), rabbit polyclonal anti-p53 (diluted 1:1.000; Santa Cruz Biotechnology, Dallas, TX), mouse monoclonal anti-p21 (diluted 1:500; Santa Cruz Biotechnology), mouse monoclonal anti-p16 (diluted 1:500; Santa Cruz Biotechnology), mouse monoclonal anti-gp91 phox (diluted 1:1.000; Santa Cruz Biotechnology), rabbit polyclonal anti-p47 phox (diluted 1:1.000; Cell Signaling Technology, Danvers, MA), rabbit polyclonal anti-p22 phox (diluted 1:1.000; Santa Cruz Biotechnology), mouse monoclonal anti-COX-1 (diluted 1:1.000; Cell Signaling Technology), mouse monoclonal anti-COX-2 (diluted 1:500; BD Biosciences), rabbit polyclonal anti-ACE (diluted 1:1000; Abbiotec), rabbit polyclonal anti-AT1 (diluted 1:1000; Santa Cruz Technology), mouse monoclonal anti-β-tubulin (diluted 1:3.000; Sigma-Aldrich), or mouse monoclonal α-actin (diluted 1:1.000; Sigma-Aldrich) overnight at 4°C. After washing, membranes were incubated with the secondary antibody (peroxidase-labeled antirabbit and anti-mouse immunoglobulin G, dilution of 1:5000; Cell Signaling Technology) at room temperature for 60 minutes. Prestained markers (Invitrogen) were used for molecular mass determinations. Immunoreactive bands were detected by enhanced chemiluminescence (GE healthcare). The amount of protein in each lane was normalized to the housekeeping protein, α-actin or β-tubulin before the analysis was performed.
Statistical Analysis
Data are presented as mean ± SEM of n different experiments. Mean values were compared using Student's paired t test or an analysis of variance followed by the post hoc Bonferroni test to identify significant differences between treatments, using GraphPad Prism (version 5 for Microsoft windows. GraphPad software, Inc, San Diego, CA). The difference was considered to be significant when the p value was less than .05.
Results
Redox-sensitive Induction of Replicative and Premature Endothelial Senescence
Serial passaging of porcine coronary artery endothelial cells up to passage 4 (P4) resulted in a progressive induction of senescence as assessed using SA-β-gal by flow cytometry detection of C 12 -fluorescein fluorescence ( Figure 1A ). Because a NO donor (DETA-NO) and transfection with eNOS in cultured endothelial cells have been shown to decrease the number of senescent cells (25) , the possibility that the basal formation of eNOS-derived NO counteracts endothelial senescence was assessed. Treatment of endothelial cells at P1 with increasing concentrations of the eNOS inhibitor L-NAME (0.1-10 mM) significantly increased SA-β-gal activity ( Figure 1B ). In addition, the level of eNOS protein was markedly reduced in both replicative endothelial senescence at P3 and also in L-NAMEinduced premature endothelial senescence at P1 ( Figure 1C ). In contrast, the L-NAME treatment did not affect the low protein level of eNOS in P3 senescent endothelial cells ( Figure 1C ). Thus, the endogenous eNOS-derived NO formation is a key mechanism counteracting the induction of senescence.
Because oxidative stress has been shown to be an important inducer of cell senescence and the formation of eNOS-derived NO is an important mechanism limiting oxidative stress, by chemically reacting and destroying superoxide anions (26, 27) , the role of oxidative stress in both replicative and premature endothelial senescence was determined by flow cytometry using the redox-sensitive fluorescent probe dihydroethidium. The ethidium fluorescence signal was markedly increased in cells at P3 compared with cells at P1, and this effect was prevented by the antioxidant NAC ( Figure 1D ). In order to determine the source of ROS, endothelial cells were treated with pharmacological inhibitors of the major sources of ROS before DHE staining. The increased ethidium fluorescence signal was markedly reduced by apocynin (a NADPH oxidase inhibitor) and indomethacin (a cyclooxygenase inhibitor) and was not affected by L-NAME ( Figure 1D ), suggesting the involvement predominantly of NADPH oxidase and cyclooxygenases. Indeed, an overexpression of the NADPH oxidase subunits gp91 phox, p47 phox, and p22 phox and of COX-1 and COX-2 was observed in P3 cells as assessed by Western blotting (Figure 2 ). The fact that NAC, NADPH oxidase inhibitors (apocynin and VAS-2870), and indomethacin significantly reduced SA-β-gal activity, and also the increased expression of the senescence markers (p53, p21, and p16), the NADPH oxidase subunits, and COX-1 and 2 (except the increased COX-2 level, which was not affected by NAC) and the downregulation of eNOS in P3 endothelial cells, indicates that oxidative stress is an early key event promoting the imbalance by reducing the influence of the protective eNOS-derived NO pathway and increasing that of the NADPH oxidase-and COXdependent prosenescent pathways (Figures 1 and 2 ). In addition, the level of oxidative stress in cells at P1 was not affected by NAC and indomethacin, whereas it was significantly increased by the eNOS inhibitor and slightly reduced by apocynin, suggesting that eNOS-derived NO controls the basal level of oxidative stress and that NADPH oxidase appears to be a major source of ROS in nonsenescent endothelial cells.
The Local Redox-sensitive Angiotensin System Promotes Endothelial Replicative and Premature Senescence
Because oxidative stress has been shown to upregulate the expression of both ACE and ATR1 in endothelial and vascular smooth muscle cells (28, 29) , the role of the local angiotensin system in the induction of both replicative and premature endothelial senescence was determined. Exposure of endothelial cells to either the ACE inhibitor perindoprilat or the AT1R blocker losartan concentration-dependently decreased SA-β-gal activity in endothelial cells at P3 and in L-NAME-treated P1 endothelial cells (Figures 3 and  4A ). Both losartan and perindoprilat also prevented the L-NAMEinduced upregulation of p16 and p21 but not of p53 protein levels ( Figure 4E-G) . In addition, a significant upregulation of both ACE and AT1 receptor protein levels was observed in replicative senescent endothelial cells at P3 and in premature L-NAME-treated P1 senescent endothelial cells ( Figures 3C,D and 4C,D) . The fact that the antioxidant treatments (NAC, NADPH oxidase inhibitor, and COX inhibitor) prevented the upregulation of ACE and AT1 receptors in senescent endothelial cells indicates that oxidative stress is acting upstream of the local angiotensin system (Figures 3C,D and 4C,D). Moreover, perindoprilat and losartan prevented the upregulation of ACE and AT1 receptor protein levels in L-NAME-treated P1 senescent endothelial cells, suggesting that the local angiotensin system promotes in a feed forward positive manner its own expression ( Figure 4C, D) . In contrast to markers of senescence and of the angiotensin system, perindoprilat and losartan did not significantly affect the downregulation of the eNOS protein level in L-NAMEtreated P1 senescent endothelial cells ( Figure 4B ).
Crataegus Extract Delays Replicative Endothelial Senescence by Preventing the Oxidative Stressinduced Downregulation of the eNOS Pathway
Because oxidative stress is a determinant event triggering the cascade of events leading to replicative and premature endothelial senescence, experiments were performed to evaluate the potential protective effect of the Crataegus special extract WS1442. This polyphenol-rich quantified hawthorn extract has been shown previously to be a potent activator of the eNOS-derived NO formation in isolated coronary artery rings and to prevent aging-related endothelial dysfunction and oxidative stress (18, 30) . The Crataegus extract concentration-dependently reduced the increased SA-β-gal activity in cells at P2, P3, and P4 ( Figure 5A ). A significant reduction in SA-β-gal activity was already observed in response to a concentration as low as 1 µg/mL of the Crataegus extract in cells at P3 and P4 (Figure 5A,B) . The protective effect of the Crataegus treatment in cells at P3 was not observed in the presence of L-NAME ( Figure 5B ) indicating the key role of eNOS-derived NO. In addition, the serial passaging-induced downregulation of the eNOS protein level in cells at P3 and P4 was significantly reduced by the Crataegus treatment ( Figure 5C ). Furthermore, the Crataegus treatment prevented the replicative endothelial senescence-induced increase in oxidative stress in cells at P3 ( Figure 5D ), and this effect was associated with a reduced expression level of the cell cycle regulatory proteins p53, p21, and p16, the NADPH oxidase subunits (gp91 phox, p47 phox, and p22 phox), COX-1 and COX-2, and the local angiotensin system ( Figure 6 ).
Discussion
The major novel findings of the present study indicate that replicative endothelial senescence of porcine coronary artery endothelial cells is triggered by the progressive induction of a pro-oxidant state subsequent to the downregulation of the eNOS-derived NO formation associated with the upregulation of two major pro-oxidant enzymes, NADPH oxidase and COXs, and the local angiotensin system that lead to the induction of cell cycle inhibitory pathways including the p53/p21 and the p16 pathways. They also indicate that the polyphenol-rich Crataegus special extract WS1442 is able to effectively delay replicative endothelial senescence by preventing the downregulation of eNOS-derived NO formation and, hence, blunting the redox-sensitive activation of the cell cycle inhibitory pathways.
Consistent with previous studies, serial passaging of primary cultured coronary artery endothelial cells is associated with the progressive induction of senescence as indicated by the increased SA-β-gal activity and the expression of major senescence markers including p53 and its downstream target p21, a DNA damage-related cyclindependent kinase inhibitor (31) , and p16, a member of the Ink4 family of cyclin-dependent kinase inhibitor (32, 33; and present findings). The induction of replicative senescence is also associated with the downregulation of the eNOS pathway as indicated by a reduced eNOS mRNA and protein levels, eNOS activity, and NO formation (7, 34; and present findings). Moreover, several lines of evidence suggest that the blunted NO formation is an early key event triggering the signal transduction cascade leading ultimately to endothelial senescence (22; and present findings). Indeed, treatment of young endothelial cells with the eNOS inhibitor, L-NAME, promoted a pronounced premature induction of endothelial senescence as assessed by SA-β-gal activity. In addition, both the NO donor DETA-NO and transfection of eNOS into human umbilical vein endothelial cells has been shown to decrease the number of senescent endothelial cells (25) . NO has been suggested to delay endothelial senescence by increasing telomerase activity thereby preventing the alteration and the shortening of length of telomeres (35) . Alternatively, NO may also retard the induction of senescence by preventing the downregulation of eNOS expression as the eNOS inhibitor L-NAME caused a pronounced decrease of the eNOS protein level in young cells. Moreover, NO may also contribute to retard endothelial senescence by limiting the level of oxidative stress, a potent inducer of senescence, in endothelial cells. The level of oxidative stress was significantly higher in senescent P3 cells and in L-NAME-treated premature senescent P1 young cells than in control young P1 cells, and the antioxidant NAC prevented the expression of senescence markers including p53, p21, and p16 in P3 senescent cells. The pharmacological characterization of oxidative stress in P3 senescent cells has indicated a major role of NADPH oxidase and cyclooxygenases. Additionally, both NADPH oxidase protein subunit levels, gp91 phox, p47 phox, and p22 phox, and COX-1 and COX-2 protein levels were upregulated in P3 senescent cells. Previous studies have also indicated that NADPH oxidase subunits Nox1 and Nox4 are involved in the excessive formation of ROS in senescent human endothelial cells (36) . In addition, an upregulation of NADPH oxidase subunits p47 phox, Nox2, and Nox4 was observed in JunD −/− mice displaying premature vascular senescence associated with an impairment of the O 2
•-/NO balance (37) . Furthermore, Nox4 gene interference using small-hairpin RNA was able to delay replicative senescence in human umbilical vein endothelial cells (38) . Previous studies have also shown that COX-2 contributed to the establishment and maintenance of senescence of human fibroblasts (39), and a low dose of aspirin delayed the onset of senescence in circulating endothelial progenitor cells (40) .
The fact that increases in NADPH oxidase and COX protein levels in P3 senescent cells were prevented by NAC, apocynin, and indomethacin indicates that ROS perpetuate a sustained pro-oxidant state in senescent cells by upregulating major pro-oxidant enzymes. In addition, because NAC, apocynin, and indomethacin also prevented the downregulation of eNOS protein levels in senescent P3 cells, it implies that ROS have also a determinant role. Altogether these findings indicate that oxidative stress is a key early event triggering the downregulation of the endothelial NO formation in conjunction with the upregulation of both the NADPH oxidase-and the COX-derived formation of ROS leading ultimately to the induction of replicative senescence. Recent findings suggest a role of p53 in the mechanism underlying the downregulation of eNOS. Indeed, p53 has been shown to downregulate KLF2 expression, a positive transcriptional regulator of eNOS expression (41) , either directly by transcriptional repression (11) or indirectly by upregulation of p66shc, a negative transcriptional regulator of KLF2 (42) . Although the origin of the imbalance between NO and oxidative stress in replicative senescence remains unclear, it may be related to the fact that absence of schear stress, the major physiological stimulus for eNOS expression and NO formation is missing in cultured endothelial cells (43) . Previous studies have indicated that shear stress prevents in part the downregulation of eNOS mRNA and protein levels in cultured human aortic endothelial cells (34) .
Activation of the local angiotensin system has been shown to contribute to the increased level of oxidative stress observed in pathological arteries such as in old arteries and in arteries from hypertensive animals and humans mostly by an AT1R-mediated activation of NADPH oxidase (44, 45) . Moreover, angiotensin II has been reported to be a potent inducer of premature senescence in endothelial cells (46) . In the present study, endothelial senescence was associated with an upregulation of the local angiotensin system as indicated by increased expression levels of ACE and AT1 receptors in both replicative and premature senescent endothelial cells. Of interest, both responses were prevented by antioxidant treatments indicating the involvement of a redox-driven mechanism. Furthermore, the angiotensin system appears to act in a feed forward manner because it contributed to upregulate both ACE and AT1 receptors in premature senescent endothelial cells. The local angiotensin system has a determinant role in the induction of both replicative and premature endothelial senescent as indicated by the fact that both the ACE inhibitor and the AT1 receptor blocker concentration-dependently reduced SA-β-gal activity.
The present study provides also evidence that a polyphenol-rich standardized Crataegus extract protects endothelial cells against replicative senescence in an eNOS-dependent manner because the protective effect of the Crataegus extract was abrogated by the blockade of NO formation by the eNOS inhibitor, L-NAME. The protective effect of the Crataegus extract on endothelial senescence was observed at concentrations as low as 1 µg/mL and was associated with a reduced level of oxidative stress and an improved expression level of eNOS protein in senescent endothelial cells. The beneficial effect most likely reflects the ability of the Crataegus extract to prevent the upregulation of the pro-oxidant enzymes including NADPH oxidase and COXs in senescent endothelial cells leading ultimately to a reduced level of oxidative stress and, hence, the maintenance of the endothelial formation of NO. These findings are consistent with previous ones indicating that the Crataegus extract is a potent activator of eNOS in endothelial cells (30) and that it reduced aging-related vascular oxidative stress (18) . In addition, a red wine polyphenolic extract has also been shown to reduce oxidative stressinduced endothelial cell senescence (10) , and resveratrol to prevent H 2 O 2 -induced senescence of human umbilical vein endothelial cells (47) and the onset of endothelial progenitor cell senescence through an increase of telomerase activity (48) .
Endothelial senescence has been observed in atheroscleroticprone regions (5, 7, 49) that are generally exposed to disturbed blood flow, such as arterial bifurcations (50) . Moreover, disturbed blood flow has been shown to promote premature senescence in endothelial cells through a p53/p21 pathway (51), to induce oxidative stress, Figure 6 . The Crataegus extract (WS1442) prevents the overexpression of cell cycle regulatory proteins, NADPH oxidase subunits, cyclooxygenase isoforms, and local angiotensin system components in P3 endothelial cells. Young (P1) and senescent (P3) endothelial cells were treated with either vehicle or the Crataegus extract (10 µg/mL) before determination of protein expression by Western blotting. Results are presented as representative immunoblots (upper panels) and corresponding cumulative data (lower panels) for expression of (A) cell cycle regulatory proteins p53, p21, and p16, (B) NADPH oxidase subunits gp91 phox, p47 phox, and p22 phox, (C) cyclooxygenase isoforms COX-1 and COX-2, and (D) local angiotensin system components angiotensin-converting enzyme and AT1R. *p < .05 versus control P1 cells and #p < .05 versus control P3 cells (n = 3). due at least in part to NADPH oxidase overexpression, and to reduce eNOS expression in endothelial cells, leading to a reduced NO bioavailability (50) . Because NO is able to inhibit the induction of endothelial senescence (25) , these findings suggest that disturbed blood flow at sites of arterial bifurcations promotes premature endothelial senescence through reduced NO bioavailability leading to activation of the p53/p21 pathway. Thus, the reduction of cellular oxidative stress and activation of the endothelial NO formation by the Crataegus extract seems to be an interesting approach to prevent the induction of premature senescence. The possibility that such a beneficial effect helps to maintain endothelial protection at sites of disturbed flow still remains to be investigated.
In conclusion, the present findings indicate that the redox-sensitive local angiotensin system triggers both replicative and premature endothelial senescence by causing an imbalance between the protective eNOS-derived NO pathway and the NADPH oxidase-and COX-mediated oxidative stress-dependent cycle inhibitory pathways (p53/p21, and p16). They further indicate that the Crataegus treatment is able to delay replicative endothelial senescence by maintaining an optimal balance between eNOS-derived NO formation and the endogenous level of oxidative stress. 
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